Join Growin Stock Community!

Hcw biologics inc.HCWB.US Overview

US StockHealthcare
(No presentation for HCWB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

HCWB AI Insights

HCWB Overall Performance

HCWB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

HCWB Recent Performance

-7.51%

Hcw biologics inc.

0.05%

Avg of Sector

-0.31%

S&P500

HCWB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

HCWB Key Information

HCWB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

HCWB Profile

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Price of HCWB

HCWB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

HCWB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.20
PB Ratio
2.80
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-14279.03%
Revenue Growth (YoY)
-92.55%
Profit Growth (YoY)
-92.55%
3-Year Revenue Growth
-79.49%
3-Year Profit Growth
-79.49%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.20
PB Ratio
2.80
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-14279.03%
Revenue Growth (YoY)
-92.55%
Profit Growth (YoY)
-92.55%
3-Year Revenue Growth
-79.49%
3-Year Profit Growth
-79.49%

  • When is HCWB's latest earnings report released?

    The most recent financial report for Hcw biologics inc. (HCWB) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HCWB's short-term business performance and financial health. For the latest updates on HCWB's earnings releases, visit this page regularly.

  • What is the operating profit of HCWB?

    According to the latest financial report, Hcw biologics inc. (HCWB) reported an Operating Profit of -3.29M with an Operating Margin of -105,483.05% this period, representing a growth of 10.79% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is HCWB's revenue growth?

    In the latest financial report, Hcw biologics inc. (HCWB) announced revenue of 3.12K, with a Year-Over-Year growth rate of -96.34%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does HCWB have?

    At the end of the period, Hcw biologics inc. (HCWB) held Total Cash and Cash Equivalents of 1.1M, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does HCWB go with three margins increasing?

    In the latest report, Hcw biologics inc. (HCWB) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -105,483.05%%, and net margin of -145,925.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess HCWB's profit trajectory and future growth potential.

  • Is HCWB's EPS continuing to grow?

    According to the past four quarterly reports, Hcw biologics inc. (HCWB)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -2.02. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of HCWB?

    Hcw biologics inc. (HCWB)'s Free Cash Flow (FCF) for the period is -3.24M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 9.33% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.